StockNews.com Upgrades Sarepta Therapeutics (NASDAQ:SRPT) to Buy

StockNews.com upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a hold rating to a buy rating in a research report report published on Tuesday.

A number of other analysts have also recently weighed in on the company. Jefferies Financial Group assumed coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They issued a “buy” rating and a $165.00 price target on the stock. Raymond James reiterated an “outperform” rating and set a $150.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Barclays cut their price target on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Guggenheim upped their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, UBS Group lifted their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. One analyst has rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $181.33.

Sarepta Therapeutics Stock Down 3.0 %

NASDAQ SRPT opened at $114.32 on Tuesday. Sarepta Therapeutics has a 1-year low of $76.61 and a 1-year high of $173.25. The company has a market capitalization of $10.92 billion, a price-to-earnings ratio of 91.46 and a beta of 0.81. The stock’s 50 day moving average is $125.15 and its two-hundred day moving average is $132.80. The company has a current ratio of 3.84, a quick ratio of 3.19 and a debt-to-equity ratio of 0.93.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Michael Andrew Chambers acquired 37,038 shares of Sarepta Therapeutics stock in a transaction on Friday, August 16th. The shares were purchased at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now owns 284,034 shares in the company, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Michael Andrew Chambers bought 37,038 shares of Sarepta Therapeutics stock in a transaction on Friday, August 16th. The shares were purchased at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Riggs Asset Managment Co. Inc. lifted its holdings in Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 75 shares in the last quarter. CIBC Asset Management Inc raised its position in shares of Sarepta Therapeutics by 3.3% during the third quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after purchasing an additional 86 shares during the period. EP Wealth Advisors LLC lifted its holdings in shares of Sarepta Therapeutics by 2.1% during the 2nd quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock valued at $774,000 after purchasing an additional 103 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its position in shares of Sarepta Therapeutics by 1.9% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock valued at $1,000,000 after purchasing an additional 120 shares during the period. Finally, Oppenheimer Asset Management Inc. increased its stake in Sarepta Therapeutics by 3.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock worth $557,000 after purchasing an additional 145 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.